<DOC>
	<DOCNO>NCT01573442</DOCNO>
	<brief_summary>This randomized phase III trial study testosterone see well work compare placebo treat postmenopausal patient arthralgia ( joint pain ) cause anastrozole letrozole . Testosterone may help relieve moderate severe arthralgia associate use aromatase inhibitor , anastrozole letrozole .</brief_summary>
	<brief_title>Testosterone Treating Postmenopausal Patients With Arthralgia Caused Adjuvant Aromatase Inhibitor Treatment</brief_title>
	<detailed_description>This randomize , placebo-controlled , phase III trial evaluate subcutaneous testosterone alleviation aromatase inhibitor induce arthralgia . A parallel group design utilize two-arm study : subcutaneous testosterone vs. placebo . Patients stratify accord baseline pain score ( 5-6 vs. 7-10 ) age ( &lt; 50 vs. 50-60 vs. &gt; 60 ) . The primary objective determine whether testosterone reduce AI-induced arthralgia associate joint symptom . The secondary objective explore whether testosterone acceptable safety tolerability profile , particular reference androgenic adverse event include acne , hirsutism , alopecia . Patients follow six month define protocol .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hot Flashes</mesh_term>
	<mesh_term>Arthralgia</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>1 . Age ≥ 18 year 2 . Receiving anastrozole ( 1mg ) letrozole ( 2.5 mg ) orally day , ≥ 21 day prior registration plan continue throughout duration study 3 . Body Mass Index ( BMI ) 18 35 kg/m^2 4 . Women undergone total mastectomy breast conserving surgery primary breast cancer +/chemo , +/radiotherapy . 5 . Must BOTH ER PR receptorpositive tumor BOTH must ≥26 % positive . Alternatively , ER PR determine Allred score , score need 5 high 6 . Women postmenopausal surgery , radiotherapy presence natural amenorrhea ≥ 12 month 7 . ≥ 5/10 arthralgia ( hand , wrist , knee , hip ) treat anastrozole letrozole felt patient cause aromatase inhibitor define protocol . Note : Patients may , may , take nonopioid analgesic 8 . Ability complete questionnaire ( ) assistance 9 . ECOG Performance Status ( PS ) 0 , 1 2 10 . Willing provide inform write consent 11 . Willing return Alliance enrol institution followup 12 . Willing provide blood sample correlative research purpose 13 . Laboratory value prior registration define protocol : 1 . Creatinine ≤1.5 x ULN 2 . Hemoglobin &gt; 11 g/dL 3 . WBC &gt; 3.0 4 . Platelet Count &gt; 100,000 5 . SGOT ( AST ) ≤ 1.5 x ULN 1 . Presence residual recurrent cancer ( locally metastatic ) 2 . Diabetes mellitus glucose intolerance , define fast glucose &gt; 125 mg/dL 3 . History coronary artery disease ( angina myocardial infarction ) 4 . Patients hormone replacement therapy ( HRT ) ≤ 4 week prior registration . This include use vaginal estrogen therapy . 5 . Known hypersensitivity component testosterone . 6 . Prolonged systemic corticosteroid treatment , except topical application ( e.g . rash ) , inhale spray ( e.g . obstructive airway disease ) , eye drop local insertion ( e.g . intraarticular ) . Note : Short duration ( &lt; 2 week ) systemic corticosteroid allow ( e.g . chronic obstructive pulmonary disease ) within 30 day prior registration . 7 . Receiving investigational agent 8 . History deep venous thrombosis thromboembolism 9 . Concurrent use aromatase inhibitor exemestane , structurally similar androgen 10 . Concurrent radiation therapy chemotherapy 11 . Current plan use cyclosporine , anticoagulant , oxphenbutazone , insulin , oral injectable vitamin D dose 4,000IU/day , tamoxifen</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>hot flash</keyword>
	<keyword>musculoskeletal complication</keyword>
	<keyword>sexual dysfunction</keyword>
	<keyword>estrogen receptor-positive breast cancer</keyword>
	<keyword>progesterone receptor-positive breast cancer</keyword>
	<keyword>arthralgia</keyword>
	<keyword>stage IA breast cancer</keyword>
	<keyword>stage IB breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
</DOC>